


Allitinib

ALTERNATE NAMES: AST-1306; N-(4-(3-Chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)acrylamide; N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]prop-2-enamide

CATALOG #: B3002-1 1 mg
B3002-5 5 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₄H₁₈ClFN₄O₂

MOLECULAR WEIGHT: 448.9

CAS NUMBER: 897383-62-9

APPEARANCE: Solid

PURITY: >98%

SOLUBILITY: ~20 mg/ml in DMSO

DESCRIPTION: Allitinib is a novel anilino-quinazoline compound that inhibits ErbB tyrosine kinases: epidermal growth factor receptor (EGFR) and ErbB2. It inhibits EGFR and ErbB2 with IC₅₀ values of 0.5 nM and 3 nM in cell-free assays. It inhibits the phosphorylation of EGFR and ErbB2 and downstream signaling in human cancer cells. It potently inhibits cell lines expressing high levels of ErbB2 such as Calu-3 lung adenocarcinoma and BT474 breast cancer cells with IC₅₀ values of 0.23 μM and 0.97 μM respectively. It inhibits tumor growth in the SK-OV-3 xenograft model.

STORAGE TEMPERATURE: -20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Xie, H., Lin, L., Tong, L., et al. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 6(7):e21487 (2011).

RELATED PRODUCTS:

Zanubrutinib (Cat. No. B2512)
Selpercatinib Cat. No. B2996)
Avitinib (Cat. No. B2995)
Avapritinib (Cat. No. B2999)
Branebrutinib (Cat. No. B2998)

DISCLAIMER: *FOR RESEARCH USE ONLY! Not to be used on humans.*